Gastric Cancer Growth Control by BEZ235 <i>In Vivo</i> Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake

Abstract

In conclusion, in vivo sensitivity of gastric cancer xenografts to BEZ235 did not correlate with in vitro antiproliferative activity or in vivo PI3K/mTOR target inhibition by BEZ235. In contrast, [(18)F]FLT uptake was linked to BEZ235 in vivo sensitivity. Noninvasive [(18)F]FLT PET imaging might qualify as a novel marker for optimizing future clinical testing of dual PI3K/mTOR inhibitors.